1.646.889.1200|info@lifescipublicrelations.com

Arrowhead’s Third-Generation RNAi Shows Initial Efficacy Against HBV

//Arrowhead’s Third-Generation RNAi Shows Initial Efficacy Against HBV

Arrowhead’s Third-Generation RNAi Shows Initial Efficacy Against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained $5.29 (38%) to $19.39 Thursday after reporting initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating HBV surface antigen (HBsAg) in a broad population of patients with chronic HBV infection. The biotech added $465 million in market cap on the data.

By | 2018-09-10T17:12:23-04:00 September 6th, 2018|News|Comments Off on Arrowhead’s Third-Generation RNAi Shows Initial Efficacy Against HBV

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.